Novartis job cuts to heavily impact management roles
Of the 1,400 job cuts announced by the pharma giant in Switzerland, up to half of them will involve staff in leadership positions, the company said on Monday.
For these executive roles, the consultation process has been finalised, and the first individuals concerned will be informed “in the coming weeks”, said the head of Novartis Switzerland Matthias Leuenberger at a media event in Zurich.
While Switzerland is no stranger to job cuts, such a big lay-off of management level staff is somewhat unprecedented in the country, a spokesperson for the Swiss Employees Association told the NZZ newspaper on Tuesday.
More
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure – it’s a turning point for Novartis.
The cuts – part of a worldwide restructuring that will see 8,000 jobs shelved – are part of a streamlining that will see the merger of two previously separate Novartis divisions, Innovative Pharmaceuticals and Cancer Drugs.
The company also wants to simplify its global functions in finance, human resources, legal and communications, with the goal of saving at least CHF1 billion ($1.04 billion) by 2024.
The Swiss cuts will probably not come into effect until summer 2023, due to the terms of the employee contracts, Leuenberger said on Monday. He added that while some staff are concerned about the layoffs, they are “neither frustrated nor angry”, and apparently regard the situation as an opportunity to re-orient themselves.
Leuenberger also said that fewer staff will have the option of taking early retirement compared to a previous bout of layoffs in 2018.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
This content was published on
With over 100,000 jobs listed as vacant in the first quarter of 2022, staff shortages are reaching record levels in Switzerland.
This content was published on
Around 1,500 jobs are affected in production and 700 in services. Novartis currently employs 13,000 people across Switzerland.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.